Clinical Trials Directory

Trials / Terminated

TerminatedNCT04284371

The Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) Pediatric Patients

The Prevalence of Liver Steatosis, Steatohepatitis, Fibrosis, and Hemosiderosis in Overweight and Obese US Military Dependent Pediatric Patients Using MR Elastography and Quantitative MRI

Status
Terminated
Phase
Study type
Observational
Enrollment
150 (actual)
Sponsor
The Geneva Foundation · Academic / Other
Sex
All
Age
10 Years – 17 Years
Healthy volunteers

Summary

The prevalence of liver steatosis, steatohepatitis, fibrosis, and hemosiderosis in overweight and obese US Military dependent pediatric patients using MR Elastography and Quantitative MRI

Detailed description

The purpose of this prospective study is to determine the prevalence NAFLD and of factors that have been associated with the diagnosis of fatty liver disease in overweight and obese children and adolescents and to determine the effectiveness of an intervention. In order to do this, we will also compare laboratory values and the ability/feasibility of new magnetic resonance technologies to first detect fatty liver disease and then to detect a difference in liver health between pediatric patients with a normal BMI and those with a BMI ≥85%. This study will consist of two phases and a reproducibility arm involving 19 voluntary subjects from Phase 1 and the control group. Phase I: Aim 1: To determine the prevalence and relative risk of liver fibrosis, steatosis, steatohepatitis and hemosiderosis in overweight and obese US Military dependents between ages 10 and 17 compared with normal weight controls using specialized MRI (LMS). Aim 2: To compare results between MRI-LMS and MRE and to determine feasibility of one versus the other technology. Aim 3: To compare liver health of controls and overweight/obese subjects to determine if there is a difference between groups. Aim 4: To test for various biomarkers that have been shown to have an association with NASH Phase II: Aim 1: To evaluate the effectiveness of a nine month intervention consisting of diet and exercise education on the maintenance or reduction of liver steatosis, steatohepatitis, and fibrosis. Aim 2: To establish whether early imaging can predict short-term clinical outcomes (eg development of pre-diabetes, worsening NAFLD, development of NASH, or a change in liver stiffness or fibrosis as measured by MRE and LMS, respectively). Reproducibility Arm Aim 1: To evaluate the consistency of the LMS/MRE data.

Conditions

Timeline

Start date
2016-02-10
Primary completion
2021-01-26
Completion
2021-01-26
First posted
2020-02-25
Last updated
2023-02-24

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT04284371. Inclusion in this directory is not an endorsement.